| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H30N4O |
| Molecular Weight | 366.4998 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCNC1=NC=CC=C1C(=O)N2CCN(CC3=CC=CC=C3)CC2
InChI
InChIKey=DYTOQURYRYYNOR-UHFFFAOYSA-N
InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24)
| Molecular Formula | C22H30N4O |
| Molecular Weight | 366.4998 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
NSI-189 is a novel oral drug which was developed by Neuralstem for the treatment of cognitive disorders. Now the drug is being tested in phase II of clinical trials in patients suffering from major depressive disorder. The mechanism of NSI-189 action is explained by its ability to stimulate the generation of new neurons in the hippocampus, however the exact target molecule is still unknown.
CNS Activity
Originator
Approval Year
Doses
Sourcing
|
|
ACTIVE MOIETY |
Has demonstrated the ability to stimulate neurogenesis in human hippocampal-derived neural stem cells in vitro and murine hippocampal cells in vivo.
|
Showing 1 to 1 of 1 entries